HC Wainwright Has Pessimistic Opinion of SNDX Q3 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Stock analysts at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Syndax Pharmaceuticals in a report released on Thursday, October 1st. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.53) per share for the quarter, down from their prior forecast of ($0.48). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $0.10 EPS, FY2029 earnings at $1.53 EPS and FY2030 earnings at $2.39 EPS.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.80.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $17.83 on Monday. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77. Syndax Pharmaceuticals has a fifty-two week low of $12.99 and a fifty-two week high of $25.59. The firm has a 50-day simple moving average of $19.21 and a 200-day simple moving average of $20.72. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -7.10 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business had revenue of $72.79 million during the quarter, compared to analyst estimates of $79.36 million. During the same quarter in the prior year, the firm posted ($0.83) earnings per share. The company’s revenue for the quarter was up 91.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Arizona State Retirement System lifted its holdings in shares of Syndax Pharmaceuticals by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 23,120 shares of the company’s stock worth $505,000 after acquiring an additional 642 shares during the period. Wellington Management Group LLP raised its position in shares of Syndax Pharmaceuticals by 0.5% in the 2nd quarter. Wellington Management Group LLP now owns 124,241 shares of the company’s stock worth $2,716,000 after buying an additional 655 shares during the period. Hsbc Holdings PLC boosted its holdings in Syndax Pharmaceuticals by 3.2% in the first quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock valued at $556,000 after acquiring an additional 730 shares during the last quarter. Allworth Financial LP acquired a new position in Syndax Pharmaceuticals in the second quarter valued at $26,000. Finally, Allspring Global Investments Holdings LLC grew its position in Syndax Pharmaceuticals by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 19,564 shares of the company’s stock valued at $467,000 after acquiring an additional 2,002 shares during the period.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, CEO Michael Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the sale, the chief executive officer directly owned 484,843 shares in the company, valued at $11,752,594.32. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.80% of the stock is currently owned by company insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.